ArticleActas espanolas de psiquiatria2025
Clinical Study on the Treatment of Somatisation Disorder With Repetitive Transcranial Magnetic Stimulation Combined With Venlafaxine.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSomatisation disorder (SD) is a chronic and complex mental health condition characterized by persistent somatic symptoms lacking a clear organic basis, frequently co-occurring with anxiety and depressive disorders. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is a standard pharmacotherapy, but its efficacy as monotherapy can be limited. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that has shown promise for various neuropsychiatric conditions. However, evidence regarding the combined application of rTMS and venlafaxine for SD remains scarce. This study aimed to evaluate the efficacy and safety of rTMS combined with venlafaxine in the treatment of SD.
methodsThis retrospective study analysed clinical data from 126 patients admitted with SD to the Third People's Hospital of Yichun from September 2022 to November 2023. Patients were classified into two groups according to the treatment regimens administered during hospitalization, rather than pre-specified study grouping: a treatment group (n = 63) that received venlafaxine in conjunction with rTMS, and a control group (n = 63) that received venlafaxine monotherapy. Clinical outcomes were evaluated using the Hamilton Anxiety Scale (HAMA), Symptom Checklist 90 (SCL-90), Clinical Global Impression-Severity of Illness Scale (CGI-SI) and Hamilton Depression Scale (HAMD) at baseline (T0) and at weeks 1 (T1), 2 (T2), 4 (T3) and 6 (T4) after treatment initiation. Adverse events were documented and analysed. The study analysed factors affecting treatment efficacy through univariate and multivariate logistic regression analyses.
resultsThe treatment group exhibited a statistically significant improvement in overall therapeutic efficacy relative to the control group (p < 0.05). Both groups demonstrated significant decreases in HAMD, HAMA, SCL-90 and CGI-SI scores at all post-treatment time points (T1, T2, T3 and T4) compared with baseline (T0). At each follow-up time point, the treatment group exhibited significantly lower scores on all assessment scales relative to the control group (p < 0.05). Both groups experienced adverse reactions, but the treatment group exhibited a lower incidence of these events (p < 0.05). Univariate analysis revealed that patients in the ineffective group were more likely to have received venlafaxine monotherapy, to be older and to have lower baseline HAMA (T0) scores than the effective group (all p values < 0.05). Multivariate logistic regression revealed that venlafaxine monotherapy (odds ratio [OR] = 3.181, 95% confidence interval [CI] [1.184-8.549]) and baseline HAMA score (OR = 0.784, 95% CI [0.644-0.954]) are significant factors affecting clinical efficacy (p < 0.05).
conclusionsThe combination of rTMS and venlafaxine demonstrates superior efficacy and an improved safety profile compared to venlafaxine monotherapy in treating SD, indicating its potential for wider clinical use. Clinicians should monitor patients' psychological status to reduce adverse reactions and improve treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.